Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Black Diamond Therapeutics Inc (BDTX)

Black Diamond Therapeutics Inc (BDTX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.5900 -0.0200 (-1.24%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.5700 -0.0200 (-1.26%) 19:35 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.5500
Day High
1.6000
Open 1.5900
Previous Close 1.6100 1.6100
Volume 421,200 421,200
Avg Vol 1,160,260 1,160,260
Stochastic %K 89.39% 89.39%
Weighted Alpha -74.45 -74.45
5-Day Change +0.1500 (+10.42%) +0.1500 (+10.42%)
52-Week Range 1.2000 - 7.6600 1.2000 - 7.6600
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,348
  • Shares Outstanding, K 56,677
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,680 K
  • EBIT $ -79 M
  • EBITDA $ -78 M
  • 60-Month Beta 2.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.08

Options Overview Details

View History
  • Implied Volatility 378.16% ( -45.43%)
  • Historical Volatility 74.95%
  • IV Percentile 98%
  • IV Rank 72.76%
  • IV High 492.91% on 04/23/25
  • IV Low 71.60% on 12/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 105
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 5,045
  • Open Int (30-Day) 5,738

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.20
  • Number of Estimates 5
  • High Estimate 0.93
  • Low Estimate -0.32
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +157.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +32.50%
on 04/09/25
Period Open: 1.6900
1.7100 -7.02%
on 03/26/25
-0.1000 (-5.92%)
since 03/25/25
3-Month
1.2000 +32.50%
on 04/09/25
Period Open: 2.4800
2.8200 -43.62%
on 01/31/25
-0.8900 (-35.89%)
since 01/24/25
52-Week
1.2000 +32.50%
on 04/09/25
Period Open: 5.1100
7.6600 -79.24%
on 05/06/24
-3.5200 (-68.88%)
since 04/25/24

Most Recent Stories

More News
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

BDTX : 1.5900 (-1.24%)
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High

As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.

BDTX : 1.5900 (-1.24%)
VTI : 270.64 (+0.61%)
IWM : 194.12 (+0.03%)
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

BDTX : 1.5900 (-1.24%)
Black Diamond: Q4 Earnings Snapshot

Black Diamond: Q4 Earnings Snapshot

BDTX : 1.5900 (-1.24%)
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

BDTX : 1.5900 (-1.24%)
Black Diamond: Q3 Earnings Snapshot

Black Diamond: Q3 Earnings Snapshot

BDTX : 1.5900 (-1.24%)
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

BDTX : 1.5900 (-1.24%)
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

BDTX : 1.5900 (-1.24%)
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

BDTX : 1.5900 (-1.24%)
Black Diamond: Q2 Earnings Snapshot

Black Diamond: Q2 Earnings Snapshot

BDTX : 1.5900 (-1.24%)

Business Summary

Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor...

See More

Key Turning Points

3rd Resistance Point 1.6600
2nd Resistance Point 1.6300
1st Resistance Point 1.6100
Last Price 1.5900
1st Support Level 1.5600
2nd Support Level 1.5300
3rd Support Level 1.5100

See More

52-Week High 7.6600
Fibonacci 61.8% 5.1923
Fibonacci 50% 4.4300
Fibonacci 38.2% 3.6677
Last Price 1.5900
52-Week Low 1.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective